Ulka Nitin Vaishampayan, MBBS, discusses the FGFR inhibitor erdafitinib (Balversa) and the importance of genetic/genomic testing in bladder cancer.
Erdafitinib is approved by the FDA for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy. Vaishampayan stresses how it is crucial that patients with bladder cancer receive genetic testing to determine their eligibility for this treatment should they progress on first-line chemotherapy.
Vaishampayan is director, Phase I Program, Rogel Cancer Center, Michigan Medicine, and professor of Internal Medicine, University of Michigan.
Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma
April 12th 2023The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.
Rapid genetic testing model found feasible for patients with prostate cancer
March 31st 2023"In our sample, nearly 10% of patients [with prostate cancer] had a gene variant that made them eligible for effective new therapies, with faster results than traditional referral for genetic testing and counseling,” said Maria I. Carlo, MD.
2 Clarke Drive
Cranbury, NJ 08512